Abstract: A brake system for an electric wheel drive unit has a housing that can be attached securely to the vehicle frame. The housing has a flange region and a shaft-like wheel carrier region secured to the flange region. A first brake component is connected to the housing and includes a first support part attached directly on a radial outer side of the wheel carrier region and a first brake disc element rotationally fixed to the first support part. A second brake component is rotatably mounted relative to the housing and has a second support part and a second brake disc element rotationally fixed to the second support part. A hydraulic actuation device is provided with one or more pressure pistons arranged. A sliding element is provided for moveably coupling the pressure pistons with one of the brake disc elements.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: An electric axle drive unit for a motor vehicle, having an electric motor with a stator that is fixedly received in a housing, and a rotor that is rotatably mounted relative to the stator and rotationally coupled or coupleable to a wheel hub. A brake device is operatively connected to the wheel hub. The brake device has a first brake component fixedly supported on the housing, a second brake component rotationally fixed to the wheel hub that is frictionally connectable to the first brake component, and an actuation unit that applies a braking force that interconnects the brake components. One of the brake components has a brake disc element rotationally fixed to a support part and is displaceably received in the axial direction of a rotational axis of the wheel hub relative to the support part.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: An apparatus with an integrated circuit (IC) chip can provide protection against attacks on a cryptographic coprocessor. An attacker can compromise a cryptographic coprocessor by, for instance, obtaining a private encryption key or instruction code. To combat these attacks, example implementations store information in encrypted form. The information may correspond to data, instruction code, or intermediate values located in state registers. To securely and quickly “erase” such stored information, the cryptographic coprocessor can change the encryption key. In other example implementations, random numbers are provided with two different levels of “randomness quality” that is appropriate for different types of procedures. A cryptographic coprocessor can include two registers that store randomized bits in accordance with the two different quality levels for rapid access during cryptographic operations.

Abstract: In human-powered vehicles, e.g., bicycles, etc., it is customary to use drum brakes, disc brakes or shoe brakes. Each of the braking systems has different advantages in terms of braking effect, system costs, ease of maintenance, etc. A brake unit with a modified structure for a vehicle is provided. For this purpose, a brake unit 14 for a vehicle 1 is disclosed, having a housing 15, having a brake body device 23, wherein the brake body device 23 supports a stationary brake partner of a brake apparatus 12 for the vehicle 1, wherein the housing 15 and/or the brake body device 23 defines a main axis H, having an actuator for moving the brake body device relative to the housing 15 in order to generate a braking force, wherein the stationary brake partner is formed as a brake disc 13.

Abstract: In order to simplify the starting-up of a transport device in the form of a long-stator linear motor, a thermal design and/or an electrical design and/or a mechanical design of the transport device is checked using a time course of the electrical control variable of the drive coils for producing a product flow, and, before starting-up, a transport device configuration having a thermal and/or electrical and/or mechanical configuration is changed if the product flow cannot be implemented due to the thermal design and/or electrical design and/or mechanical design.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to a method (100) for providing a storage capacity reserve in a traction battery (20) for an electrically driven motor vehicle (50), preferably commercial vehicle, for an upcoming downhill drive. The method (100) comprises detecting (S1) whether an electric charging operation of the traction battery (20) by means of an external charging source (60) is imminent, and determining (S2) one or more possible downhill routes (G1, G2) for an imminent downhill drive after the electric charging operation. The method (100) further comprises predicting (S3) one or more amounts of recuperated energy that will be recuperated by the motor vehicle (50) along each of the determined downhill routes (G1, G2), and determining (S4) a maximum battery state of charge of the traction battery (20) for the charging operation using the external charging source (60) as a function of the predicted amounts of recuperated energy.

Abstract: A wheel hub drive for a vehicle, having: a drive housing; a hub output mounted rotatably relative to the drive housing; a wheel brake for the hub output that has a stationary and a rotating braking partner, the stationary braking partner being connected to the drive housing for conjoint rotation therewith, and the rotating braking partner being connected to the hub output. The two braking partners are frictionally connected in a braking state, A parking brake for fixing the hub output relative to the drive housing. The stationary and rotating brake partners being movable relative to one another when the parking brake is actuated and being frictionally connected to one another in a parked state. The has a ramp mechanism for converting a rotary movement into a linear movement in order to transfer a parking force to the stationary and/or rotating brake partner.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.